Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extended Phase 2 Study of Decitabine in Subjects With High Risk Sickle Cell Disease

NCT01375608 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT01375608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01375608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extended Phase 2 Study of Decitabine in Subjects With High Risk Sickle Cell Disease
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
February 29, 2016
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neutropenia, sickle cell disease